Effects of OP-41483・α-CD, a prostacyclin analog, in the treatment of congestive refractory heart failure: Efficacy as a vasodilator Masahito Moriuchi 1 , Satoshi Saito 1 , Yasuo Tamura 1 , Junko Honye 1 , Tatsuo Ando 1 , Naoto Kaseda 1 , Masazumi Tsuji 1 , Sei Yumikura 1 , Kazuhira Hibiya 1 , Yukio Ozawa 1 , Michinobu Hatano 1 1The Second Department of Internal Medicine, Nihon University School of Medicine pp.195-200
Published Date 1986/2/15
DOI https://doi.org/10.11477/mf.1404204825
  • Abstract
  • Look Inside

 To assess acute hemodynamic effects of OP-41483・α-CD (OP), a stable prostacyclin analog, in patients with congestive heart failure (CHF), OP was administered in 10 patients with CHF resistant to conventional therapy (six with dilated cardiomyopathy and four with myocardial infarction). Hemodynamic changes were evaluated before and at 30 min after OP administration.

 OP (20ng/kg/min) caused an increase in cardiac index (1.91±0.10 to 2.54±0.10 liters/min/ M2, p< 0.01), stroke volume index (22.4±2.3 to 30.9±2.3ml/M2, p< 0.01) and stroke work index (18.9±2.4 to 25.9±2.4g・m/M2, p< 0.01) and a decrease in pulmonary arterial diastolic pressure (24.1±2.1 to 18.3±1.3mmHg, p< 0.01) and mean right atrial pressure (7.6±1.0 to 4.2±1.0 mmHg, p< 0.05). Mean arterial pressure (86.7± 4.2 to 81.1±4.3mmHg, p< 0.01) and double product (10.3±1.1 to 9.3±0.9×103mmHg・beats/ min, p< 0.05) decreased with no change in heart rate. Both systemic and pulmonary vascular resistance also decreased from 2270±113 to 1604±56 dynes・sec/cm5 (p< 0.01) , and from 240±47 to 147±19 dynes・sec/cm5 (p< 0.05) respectively.

 Seven of ten patients became flushed, but no patients experienced severe adverse side effects that necessitated to stop the infusion.

 These results suggested that OP is a potent vasodilator with both arterial and venous effects and the clinical use of OP is effective and safe in the treatment of CHF.

Copyright © 1986, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1200 印刷版ISSN 0452-3458 医学書院